The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Does disease burden affect outcome in de novo versus secondary AML?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Claudia Núñez-Torrón, Hospital Universitario Ramón y Cajal, Madrid, ES. We asked, Does disease burden affect outcome in de novo versus secondary AML?

Does disease burden affect outcome in de novo versus secondary AML?

Patients with secondary leukemia are considered to be a group of higher risk compared to those with de novo AML, due to their advanced age, lower rates of complete remission, and adverse cytogenetic risk profile. Núñez-Torrón reviews a study investigating event-free and overall survival, the impact of leukemia type, and achieving complete remission before transplant.

 

Share: